Cancer
Conditions
Keywords
cancer, solid tumor
Brief summary
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Interventions
DRUGARQ 501
Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
Sponsors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * Has previous participated in a clinical trial with ARQ 501 and is eligible for continued treatment
Exclusion criteria
* Have not received previous treatment with ARQ 501 under a treatment protocol * Uncontrolled intercurrent illness, uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501 | No time frame |
Secondary
| Measure | Time frame |
|---|---|
| To collect additional safety and tolerability information for ARQ 501 treatment | No time frame |
Countries
United States
Outcome results
None listed